31,000 Shares in Abivax SA Sponsored ADR $ABVX Acquired by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 31,000 shares of the company’s stock, valued at approximately $2,632,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABVX. UBS Group AG boosted its position in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Abivax in the third quarter valued at $38,827,000. Boothbay Fund Management LLC raised its stake in shares of Abivax by 52.5% during the 2nd quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock worth $6,659,000 after buying an additional 299,770 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Abivax during the 3rd quarter worth $16,106,000. Finally, Woodline Partners LP boosted its position in shares of Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after buying an additional 153,788 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Trading Down 1.3%

Abivax stock opened at $115.50 on Friday. The stock has a 50-day moving average price of $118.99 and a 200 day moving average price of $108.69. Abivax SA Sponsored ADR has a 52 week low of $4.77 and a 52 week high of $148.83. The stock has a market cap of $9.13 billion, a PE ratio of -27.63 and a beta of 1.00. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million for the quarter. Equities research analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Truist Financial set a $140.00 price objective on shares of Abivax in a research note on Monday, November 24th. BTIG Research restated a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Citigroup reissued a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and an average price target of $134.75.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.